Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Medtronic
Healthtrust
Argus Health
Covington
Merck
UBS
Baxter
Farmers Insurance

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,323,195

« Back to Dashboard

Which drugs does patent 7,323,195 protect, and when does it expire?

Patent 7,323,195 protects MYTESI and is included in one NDA.

This patent has eighteen patent family members in thirteen countries.
Summary for Patent: 7,323,195
Title:Enteric formulations of proanthocyanidin polymer antidiarrheal compositions
Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.
Inventor(s): Rozhon; Edward James (El Granada, CA), Khandwala; Atul S. (San Carlos, CA), Sabouni; Akram (Fairport, NY), Balwani; Gul P. (Fremont, CA), Chan; Jody Wai-Han (Mountain View, CA), Sesin; David F. (San Carlos, CA)
Assignee: Napo Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:10/919,969
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,323,195

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Napo Pharms Inc MYTESI crofelemer TABLET, DELAYED RELEASE;ORAL 202292-001 Dec 31, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,323,195

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,341,744 Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer ➤ Sign Up
8,574,634 Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
QuintilesIMS
Merck
McKesson
Farmers Insurance
Cantor Fitzgerald
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.